Brookstone Capital Management Sells 422 Shares of Humana Inc. (NYSE:HUM)

Brookstone Capital Management cut its position in Humana Inc. (NYSE:HUM) by 38.5% in the third quarter, HoldingsChannel.com reports. The firm owned 674 shares of the insurance provider’s stock after selling 422 shares during the period. Brookstone Capital Management’s holdings in Humana were worth $213,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of HUM. CarsonAllaria Wealth Management Ltd. boosted its position in shares of Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after purchasing an additional 39 shares in the last quarter. Atwood & Palmer Inc. acquired a new stake in Humana in the third quarter worth about $29,000. Hantz Financial Services Inc. purchased a new stake in shares of Humana during the second quarter worth about $35,000. Family Firm Inc. acquired a new position in shares of Humana during the second quarter valued at about $37,000. Finally, Hollencrest Capital Management purchased a new position in shares of Humana in the 2nd quarter valued at approximately $40,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Price Performance

Shares of NYSE HUM opened at $257.60 on Wednesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66. The firm has a fifty day moving average of $321.04 and a 200 day moving average of $339.45. The firm has a market cap of $31.04 billion, a PE ratio of 16.04, a PEG ratio of 1.91 and a beta of 0.50. Humana Inc. has a one year low of $213.31 and a one year high of $530.54.

Humana (NYSE:HUM) last released its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, topping analysts’ consensus estimates of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The business had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. During the same quarter in the previous year, the company earned $8.94 earnings per share. The company’s quarterly revenue was up 10.4% on a year-over-year basis. As a group, research analysts predict that Humana Inc. will post 16.06 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.37%. The ex-dividend date of this dividend is Monday, September 30th. Humana’s payout ratio is 22.04%.

Wall Street Analyst Weigh In

Several research firms have weighed in on HUM. Truist Financial dropped their target price on shares of Humana from $400.00 to $260.00 and set a “hold” rating on the stock in a research report on Friday, October 11th. Cantor Fitzgerald reissued a “neutral” rating and set a $395.00 price objective on shares of Humana in a report on Tuesday, October 1st. Morgan Stanley assumed coverage on Humana in a research note on Monday, June 24th. They issued an “equal weight” rating and a $374.00 target price for the company. Leerink Partners downgraded Humana from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $400.00 to $250.00 in a research note on Wednesday, October 2nd. Finally, Leerink Partnrs cut Humana from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. One equities research analyst has rated the stock with a sell rating, nineteen have given a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $315.33.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.